uniQure N.V.
Developing AAV gene therapies for severe neurologic and rare genetic diseases, led by AMT-130 in Huntington's disease.
Neurology & rare genetic disease · AAV gene therapy · Pivotal Phase 1/2
Developing AAV gene therapies for severe neurologic and rare genetic diseases, led by AMT-130 in Huntington's disease.
Neurology & rare genetic disease · AAV gene therapy · Pivotal Phase 1/2